Welcome to Oncternal Therapeutics

 

With a pipeline that includes two clinical-stage products, we’re committed to translate pioneering areas of cancer research into approved therapies that can be used to treat multiple cancer types.

We are working quickly to advance our clinical programs, leveraging our team’s strong experience and a network of academic collaborations.


Latest News

 

Clinical-Stage Products
for Rare Cancers

We are recruiting patients with CLL

for a Phase 1 study of Cirmtuzumab, our anti-ROR1 monoclonal antibody.

Participate in Our Trial